Acrux in dire need of booster shot
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Acrux (ACR) suffered its worst sell-off in 14 months on a disappointing sales update on its flagship testosterone treatment drug.
The stock crashed 12.5% to its lowest level this calendar year of $2.74 at 10.30 AEST when management warned that growth in the global testosterone market continues to slow and market share for its drug Axiron, which is exclusively distributed by Eli Lilly, is flattening.
The potential bad news was flagged in our article yesterday, although it has come a little sooner than we had anticipated. Investors will be keen on hearing what other growth plans the company has at its AGM on November 21.
Eli Lilly reported sales of Axiron came in at $US40.6 million in the September quarter compared with $US47.1 million in the previous quarter.
The fact that Eli Lilly will pay Acrux $US25 million as milestone payment provides little comfort for investors.
Acrux is the worst performer in the Uncapped 100 this morning.